Dinesen, A., Winther, A., Wall, A., Märcher, A., Palmfeldt, J., Chudasama, V., Wengel, J., Gothelf, K. V., Baker, J. R. & Howard, K. A. (2022). Albumin Biomolecular Drug Designs Stabilized through Improved Thiol Conjugation and a Modular Locked Nucleic Acid Functionalized Assembly. Bioconjugate Chemistry, 33(2), 333-342. https://doi.org/10.1021/acs.bioconjchem.1c00561

Fuchs, E., Rudnik-Jansen, I., Dinesen, A., Selnihhin, D., Mandrup, O. A., Thiam, K., Kjems, J., Pedersen, F. S. & Howard, K. A. (2022). An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension. Acta Biomaterialia, 153, 411-418. https://doi.org/10.1016/j.actbio.2022.09.048

Märcher, A., Kumar, V., Andersen, V. L., El-Chami, K., Nguyen, T. J. D., Skaanning, M. K., Rudnik-Jansen, I., Nielsen, J. S., Howard, K. A., Kjems, J. & Gothelf, K. V. (2022). Functionalized Acyclic (l)-Threoninol Nucleic Acid Four-Way Junction with High Stability In Vitro and In Vivo. Angewandte Chemie - International Edition, 61(24), Article 202115275. https://doi.org/10.1002/anie.202115275

Glud, E. N., Rasmussen, M., Zhang, Y., Mandrup, O. A., Salachan, P. V., Borre, M., Sørensen, K. D. & Howard, K. A. (2022). Identification of a high-risk immunogenic prostate cancer patient subset as candidates for T-cell engager immunotherapy and the introduction of a novel albumin-fused anti-CD3 × anti-PSMA bispecific design. British Journal of Cancer, 127(12), 2186-2197. https://doi.org/10.1038/s41416-022-01994-1

Symons, R. A., Colella, F., Collins, F. L., Rafipay, A. J., Kania, K., McClure, J. J., White, N., Cunningham, I., Ashraf, S., Hay, E., Mackenzie, K. S., Howard, K. A., Riemen, A. H. K., Manzo, A., Clark, S. M., Roelofs, A. J. & De Bari, C. (2022). Targeting the IL-6-Yap-Snail signalling axis in synovial fibroblasts ameliorates inflammatory arthritis. Annals of the Rheumatic Diseases, 81(2), 214-224. https://doi.org/10.1136/annrheumdis-2021-220875

Hangiu, O., Compte, M., Dinesen, A., Navarro, R., Tapia-Galisteo, A., Mandrup, O. A., Erce-Llamazares, A., Lázaro-Gorines, R., Nehme-Álvarez, D., Domínguez-Alonso, C., Harwood, S. L., Alfonso, C., Blanco, B., Rubio-Pérez, L., Jiménez-Reinoso, A., Díez-Alonso, L., Blanco, F. J., Sanz, L., Howard, K. A. & Álvarez-Vallina, L. (2022). Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity. iScience, 25(9), Article 104958. https://doi.org/10.1016/j.isci.2022.104958

Mandrup, O. A. & Howard, K. (2021). Bioengineered solutions to improve cancer immunotherapies. Therapeutic Delivery, 12(5), 339-341 . https://doi.org/10.4155/tde-2021-0019

Rudnik-Jansen, I. & Howard, K. (2021). FcRn expression in cancer: Mechanistic basis and therapeutic opportunities. Journal of Controlled Release, 337, 248-257. https://doi.org/10.1016/j.jconrel.2021.07.007

Walther, R., Monge, P., Pedersen, A., Benderoth, A., Pedersen, J., Farzadfard, A., Mandrup, O., Howard, K., Otzen, D. & Zelikin, A. N. (2021). Per-glycosylation of the Surface-Accessible Lysines: One-Pot Aqueous Route to Stabilized Proteins with Native Activity. ChemBioChem, 22(14), 2478-2485. https://doi.org/10.1002/cbic.202100228

Mandrup, O. A., Ong, S. C., Lykkemark, S., Dinesen, A., Rudnik-Jansen, I., Dagnæs-Hansen, N. F., Andersen, J. T., Alvarez-Vallina, L. & Howard, K. A. (2021). Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity. Communications Biology, 4(1), Article 310. https://doi.org/10.1038/s42003-021-01790-2

Decuzzi, P., Peer, D., Di Mascolo, D., Palange, A. L., Manghnani, P. N., Moein Moghimi, S., Shadi Farhangrazi, Z., Howard, K. A., Rosenblum, D., Liang, T., Chen, Z., Wang, Z., Zhu, J. J., Gu, Z., Korin, N., Letourneur, D., Chauvierre, C., van der Meel, R., Kiessling, F. & Lammers, T. (2021). Roadmap on nanomedicine. Nanotechnology, 32(1), Article 012001. https://doi.org/10.1088/1361-6528/abaadb

Pilati, D. & Howard, K. (2020). Albumin-based drug designs for pharmacokinetic modulation. Expert Opinion on Drug Metabolism & Toxicology, 16(9), 783-795. https://doi.org/10.1080/17425255.2020.1801633

Larsen, M. T., Mandrup, O. A., Schelde, K. K., Luo, Y., Sørensen, K. D., Dagnæs-Hansen, F., Cameron, J., Stougaard, M., Steiniche, T. & Howard, K. A. (2020). FcRn overexpression in human cancer drives albumin recycling and cell growth: a mechanistic basis for exploitation in targeted albumin-drug designs. Journal of Controlled Release, 322, 53-63. https://doi.org/10.1016/j.jconrel.2020.03.004

Howard, K. (Accepted/In press). Multifunctional Biomolecular Drug Designs. Nanotechnology.

Kania, K., Colella, F., Riemen, A. H. K., Wang, H., Howard, K., Aigner, T., Dell’Accio, F., Capellini, T. D., Roelofs, A. J. & De Bari, C. (2020). Regulation of Gdf5 expression in joint remodelling, repair and osteoarthritis. Scientific Reports, 10(1), 157. Article 157. https://doi.org/10.1038/s41598-019-57011-8

Juul-Madsen, K., Qvist, P., Bendtsen, K. L., Langkilde, A. E., Vestergaard, B., Howard, K., Dehesa-Etxebeste, M., Paludan, S. R., Andersen, G. R., Jensen, P. H., Otzen, D. E., Romero-Ramos, M. & Vorup-Jensen, T. (2020). Size-Selective Phagocytic Clearance of Fibrillar α-Synuclein through Conformational Activation of Complement Receptor 4. Journal of Immunology, 204(5), 1345-1361. https://doi.org/10.4049/jimmunol.1900494

Schelde, K. K., Nicholls , K., Dagnæs-Hansen, F., Bunting , K., Rawsthorne, H., Andersen, B., Finnis, C., Williamson, M., Cameron, J. & Howard, K. (2019). A new class of recombinant human albumin with multiple surface thiols exhibit stable conjugation, and enhanced FcRn binding and blood circulation. Journal of Biological Chemistry, 294(10), 3735-3743. https://doi.org/10.1074/jbc.RA118.005870

Garcia, JP., Stein, J., Cai, Y., Riemers, F., Wexselblatt, E., Wengel, J., Tryfonidou, M., Yayon, A., Howard, K. & Creemers, L. B. (2019). Fibrin-hyaluronic acid hydrogel-based delivery of antisense oligonucleotides for ADAMTS5 inhibition in co-delivered and resident joint cells in osteoarthritis. Journal of Controlled Release, 294, 247-258. https://doi.org/10.1016/j.jconrel.2018.12.030

Fredsøe, J., Rasmussen, A. K. I., Laursen, E. B., Cai, Y., Howard, K. A., Pedersen, B. G., Borre, M., Mouritzen, P., Òrntoft, T. & Sørensen, K. D. (2019). Independent Validation of a Diagnostic Noninvasive 3-MicroRNA Ratio Model (uCaP) for Prostate Cancer in Cell-Free Urine. Clinical Chemistry, 65(4), 540-548. https://doi.org/10.1373/clinchem.2018.296681

Nandakumar, R., Tschismarov, R., Meissner, F., Prabakaran, T., Krissanaprasit, A., Farahani, E., Zhang, B. C., Assil, S., Martin, A., Bertrams, W., Holm, C. K., Ablasser, A., Klause, T., Thomsen, M. K., Schmeck, B., Howard, K. A., Henry, T., Gothelf, K. V., Decker, T. & Paludan, S. R. (2019). Intracellular bacteria engage a STING–TBK1–MVB12b pathway to enable paracrine cGAS–STING signalling. Nature Microbiology, 4, 701-713. https://doi.org/10.1038/s41564-019-0367-z

Hall, A., Nicholls , K., Caspersen , M. B., Skrivergaard, S., Howard, K., Karu, K., Chudasama, V. & Baker, J. R. (2019). Optimised approach to albumin-drug conjugates using monobromomaleimide-C-2 linkers. Organic & Biomolecular Chemistry, 17(34), 7870-7873. https://doi.org/10.1039/C9OB00721K

Larsen, M. T., Rawsthorne, H., Schelde, K. K., Dagnæs-Hansen, F., Cameron, J. & Howard, K. (2018). Cellular recycling-driven in vivo half-life extension using recombinant albumin fusions tuned for neonatal Fc receptor (FcRn) engagement. Journal of Controlled Release, 287, 132-141. https://doi.org/10.1016/j.jconrel.2018.07.023

Cai, Y., Makarova, A-M., Wengel, J. & Howard, K. (2018). Palmitoylated phosphodiester gapmer designs with albumin binding capacity and maintained in vitro gene silencing activity. Journal of Gene Medicine, 20(7-8), Article e3025. https://doi.org/10.1002/jgm.3025

Moein Moghimi, S. & Howard, K. (2018). Targeting Biological Barriers. Molecular Therapy, 26(4), 933-934. https://doi.org/10.1016/j.ymthe.2018.03.008

Cai, Y., López-Ruiz , E., Wengel, J., Creemers, L. & Howard, K. (2017). A hyaluronic acid-based hydrogel enabling CD44-mediated chondrocyte binding and gapmer oligonucleotide release for modulation of gene expression in osteoarthritis. Journal of Controlled Release, 253(May), 153-159. https://doi.org/10.1016/j.jconrel.2017.03.004

Caspersen , M. B., Kuhlmann, M., Nicholls , K., Saxton , M. J., Andersen , B., Bunting , K., Cameron, J. & Howard, K. (2017). Albumin-based drug delivery using cysteine 34 chemical conjugates; important considerations and requirements. Therapeutic Delivery, 8(7), 511-519. https://doi.org/10.4155/tde-2017-0038

Kuhlmann, M., Hamming, J. B. R., Voldum, A., Tsakiridou, G., Larsen, M. T., Schmøkel, J., Sohn, E., Bienk, K., Schaffert, D. H., Sørensen, E. S., Wengel, J., Dupont, D. M. & Howard, K. (2017). An albumin-oligonucleotide assembly for potential combinatorial drug delivery and half-life extension applications. Molecular Therapy - Nucleic Acids, 9, 284-293. https://doi.org/10.1016/j.omtn.2017.10.004

Schmidt, E. G. W., Hvam, M. L., Antunes, F., Cameron, J., Viuff, D., Andersen, B., Kristensen, N. N. & Howard, K. A. (2017). Direct demonstration of a neonatal Fc receptor (FcRn)-driven endosomal sorting pathway for cellular recycling of albumin. Journal of Biological Chemistry, 292(32), 13312-13322. https://doi.org/10.1074/jbc.M117.794248

Hvam, M. L., Cai, Y., Dagnæs-Hansen, F., Nielsen, J., Wengel, J., Kjems, J. & Howard, K. (2017). Fatty acid-modified gapmer antisense oligonucleotide and human serum albumin constructs for pharmacokinetic modulation. Molecular Therapy, 25(7), 1710-1717. https://doi.org/10.1016/j.ymthe.2017.05.009

Hansen, I., Ebbesen, M. F., Kaspersen, L., Thomsen, T. B., Bienk, K., Cai, Y., Malle, B. M. & Howard, K. (2017). Hyaluronic Acid Molecular Weight-Dependent Modulation of Mucin Nanostructure for Potential Mucosal Therapeutic Applications. Molecular Pharmaceutics, 14(7), 2359–2367. https://doi.org/10.1021/acs.molpharmaceut.7b00236

Blans, K. I. M., Hansen, M. S., Sørensen, L. V., Hvam, M. L., Howard, K., Möller, A., Wiking, L., Larsen, L. B. & Rasmussen, J. T. (2017). Pellet-free isolation of human and bovine milk extracellular vesicles by size-exclusion chromatography. Journal of Extracellular Vesicles, 6(1), Article 1294340. https://doi.org/10.1080/20013078.2017.1294340

Schmøkel, J., Voldum, A., Tsakiridou, G., Kuhlmann, M., Cameron, J., Sørensen, E. S., Wengel, J. & Howard, K. (2017). Site-selective conjugation of an anticoagulant aptamer to recombinant albumins and maintenance of neonatal Fc receptor binding. Nanotechnology, 28(20), Article 204004 . https://doi.org/10.1088/1361-6528/aa6a9b

Christiansen, S. H., Murphy, R. A., Juul-Madsen, K., Fredborg, M., Hvam, M. L., Axelgaard, E., Skovdal, S. M., Meyer, R. L., Sorensen, U. B. S., Moeller, A., Nyengaard, J. R., Norskov-Lauritsen, N., Wang, M., Gadjeva, M., Howard, K. A., Davies, J. C., Petersen, E. & Vorup-Jensen, T. (2017). The Immunomodulatory Drug Glatiramer Acetate is Also an Effective Antimicrobial Agent that Kills Gram-negative Bacteria. Scientific Reports, 7(1), Article 15653. https://doi.org/10.1038/s41598-017-15969-3

Christiansen, S. H., Zhang, X., Juul-Madsen, K., Hvam, M. L., Vad, B. S., Behrens, M. A., Thygesen, I. L., Jalilian, B., Pedersen, J. S., Howard, K., Otzen, D. E. & Vorup-Jensen, T. (2017). The random co-polymer glatiramer acetate rapidly kills primary human leukocytes through sialic-acid-dependent cell membrane damage. B B A - Biomembranes, 1859(3), 425-437. https://doi.org/10.1016/j.bbamem.2017.01.001

Larsen, M. T., Kuhlmann, M., Hvam, M. L. & Howard, K. (2016). Albumin-based drug delivery: harnessing nature to cure disease. Molecular and Cellular Therapies, 4(3), 3. https://doi.org/10.1186/s40591-016-0048-8

Bienk, K., Hvam, M. L., Pakula, M. M., Dagnæs-Hansen, F., Wengel, J., Malle, B. M., Kragh-Hansen, U., Cameron, J., Bukrinski, J. T. & Howard, K. (2016). An albumin-mediated cholesterol design-based strategy for tuning siRNA pharmacokinetics and gene silencing. Journal of Controlled Release, 232, 143-151. https://doi.org/10.1016/j.jconrel.2016.04.013

Gaglianone, N., Hvam, M. L., Aslan, H., Dong, M., Howard, K. & Ho, Y-P. (2016). Chip-Free Microscale-Incubator-Based Synthesis of Chitosan-Based Gene Silencing Nanoparticles. Particle & Particle Systems Characterization, 33(5), 279-285. https://doi.org/10.1002/ppsc.201500225

Viuff, D., Antunes, F., Evans, L., Cameron, J., Dyrnesli, H., Ravn, B. T., Stougaard, M., Thiam, K., Andersen, B., Kjærulff, S. & Howard, K. (2016). Generation of a Double Transgenic Humanised Neonatal Fc Receptor (FcRn)/Albumin Mouse to Study the Pharmacokinetics of Albumin-linked Drugs. Journal of Controlled Release, 223, 22-30. https://doi.org/10.1016/j.jconrel.2015.12.019

Li, Z., Hu, Y., Chang, M., Howard, K., Fan, X., Sun, Y., Besenbacher, F. & Yu, M. (2016). Highly porous PEGylated Bi2S3 nano-urchins as a versatile platform for in vivo triple-modal imaging, photothermal therapy and drug delivery. Nanoscale, 8(35), 16005-16016. https://doi.org/10.1039/C6NR03398A

Li, Z., Hu, Y., Jiang, T., Howard, K., Li, Y., Fan, X., Sun, Y., Besenbacher, F. & Yu, M. (2016). Human serum albumin coated Prussian blue nanoparticles as pH-/thermo-triggered drug delivery vehicles for cancer thermo-chemotherapy. Particle & Particle Systems Characterization, 33(1), 53-62. https://doi.org/10.1002/ppsc.201500189

Martirosyan, A., Olesen, M. J., Fenton, R. A., Kjems, J. & Howard, K. A. (2016). Mucin-mediated nanocarrier disassembly for triggered uptake of oligonucleotides as a delivery strategy for the potential treatment of mucosal tumours. Nanoscale, 8(25), 12599-12607. https://doi.org/10.1039/c5nr07206a

Li, Z., Hu, Y., Howard, K., Yiang, T., Fan, X., Miao, Z., Sun, Y., Besenbacher, F. & Yu, M. (2016). Multifunctional bismuth selenide nanocomposites for anti-tumor thermo-chemotherapy and imaging. A C S Nano, 10(1), 984-997. https://doi.org/10.1021/acsnano.5b06259

Li, Z., Liu, J., Howard, K., Fan, X., Chang, M., Sun, Y., Besenbacher, F. & Yu, M. (2016). Multimodal Imaging-Guided Antitumor Photothermal Therapy and Drug Delivery Using Bismuth Selenide Spherical-Sponge. A C S Nano, 10(10), 9646–9658. https://doi.org/10.1021/acsnano.6b05427

Petersen, S., Kläning, E., Andersen, B., Cameron, J., Sørensen, E. S. & Howard, K. (2016). Neonatal Fc Receptor Binding Tolerance toward the Covalent Conjugation of Payloads to Cysteine 34 of Human Albumin Variants. Molecular Pharmaceutics, 13(2), 677–682. https://doi.org/10.1021/acs.molpharmaceut.5b00605

Howard, K. A. (2015). Albumin: The next-generation delivery technology. Therapeutic Delivery, 6(3), 265-268. https://doi.org/10.4155/tde.14.124